Docosahexaenoic acid (DMA), essentiality and requirements: Why and how to provide supplementation
Author
dc.contributor.author
Valenzuela Bonomo, Carlos
Author
dc.contributor.author
Sanhueza, B. Julio
Author
dc.contributor.author
Nieto, Susana
Admission date
dc.date.accessioned
2019-03-11T12:53:25Z
Available date
dc.date.available
2019-03-11T12:53:25Z
Publication date
dc.date.issued
2006
Cita de ítem
dc.identifier.citation
Grasas y Aceites, Volumen 57, Issue 2, 2018, Pages 229-237
Identifier
dc.identifier.issn
00173495
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/164290
Abstract
dc.description.abstract
Lipids comprize from 50-60% of the structural matter of the brain and docosahexaenoic acid (C22:6, DHA) is the most important omega-3 long-chain polyunsaturated fatty acid in the brain phospholipids comprizing 25% of the total fatty acids of the grey matter. The majority of the DHA present in the human brain is incorporated during the brain growth spurt which starts at week 26 of gestation and imposes a high demand for the fatty acid until about 2 years of age. DHA is required during brain development when neuronal and glial differentiation and migration, and active myelination and synaptogenesis take place. The fatty acid must be incorporated into the brain lipids as preformed DHA because less than 5% of its precursor (alpha linolenic acid, LNA) is converted to DHA. The human foetus has a limited ability to synthesize DHA from LNA, and therefore it must be largely supplied from maternal sources. Maternal DHA available for foetal nutrition can be provided from three main sources: adipo